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Abstract
Bronchiectasis (BE) is a chronic and heterogeneous respiratory disease that requires a multi-
dimensional scoring system to properly assess severity. The aim of this study was to com-
pare the severity stratification by 2 validated scores (BSI and FACED) in a BE cohort and to
determine their predictive capacity for exacerbations and hospitalizations. Moreover, we pro-
posed a modified version of FACED which was created to better predict the risk of exacerba-
tions in clinical practice. We performed a prospective cohort study including BE patients >18
years old with a follow-up period of 1-year. One-hundred eighty-two patients (40% males;
mean age 68) were studied. Patients were stratified according to the number of exacerba-
tions during the follow-up, and according to BSI and FACED scores. BSI classified most of
our patients as severe 99 (54.4%) or moderate 47 (25.8%), while FACED mainly classified
as mild 108 (59.3%) or moderate 61 (33.5%). BSI and FACED showed an area under ROC
curve (AUC) for exacerbations of 0.808 and 0.734; and for hospitalizations (due to BE exac-
erbations) of 0.893 and 0.809, respectively. Subsequently, we modified FACED by adding
previous exacerbations (Exa-FACED) and this new score classified patients as mild 48.4%,
moderate 34.6% and severe 17.0%, with an improved AUC for exacerbations (0.760) and
hospitalizations (0.820). Despite previous validations of BSI and FACED, they classified our
patients very differently. As expected, FACED showed poor prognostic capacity for exacer-
bations. We support the Exa-FACED score to predict the risk future exacerbations for been
easy to use in clinical practice.
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Introduction
Bronchiectasis (BE) is a chronic respiratory disease defined pathologically by irreversible and
usually progressive dilatation and destruction of the bronchi[1]. Clinically, bronchiectasis is
characterized by a persistent cough, sputum production[2], recurrent respiratory infections[3–
5], progressive loss of lung function[6, 7] and worsening in quality of life[8].
BE is a multidimensional disease, so its prognosis cannot be adequately determined by one
isolated variable. Identifying patients at risk of exacerbations and mortality is vital to optimize
their management. Two multidimensional scoring systems have been created and validated to
classify the severity of BE: the Bronchiectasis Severity Index (BSI) and the FACED scores. Both
scores embrace diverse clinical, functional, radiological and microbiological aspects that are
characteristics of the disease. BSI is relatively complex, evaluating 9 variables with different
point values to identify patients at risk of future mortality, hospital admissions and exacerba-
tions[9]. Alternatively, FACED is an easy-to-use system, incorporating 5 dichotomized param-
eters in order to classify the severity of BE according to its prognosis in terms of 5-years[10],
although during its development it has not been validated for exacerbations. Exacerbations are
incidental events that have an important role on treatment and patient´s quality-of-life, and
associated with health-related costs. Better prediction of exacerbations may provide informa-
tion to clinicians intervene in their prevention, and therefore, decrease hospitalizations and
worse outcomes.
The aims of this study were to compare the classification by the 2 scores in a larger cohort
of stable BE patients classified by the number of exacerbations and, investigate the predictive
values of both scores in terms of exacerbations and hospitalizations due to exacerbations of
BE. The FACED score was developed in a Spanish cohort[10] and is an easy-to-use score but is
less consistent for predicting exacerbations[11] than BSI, accordingly we modified the FACED
to classify better our patients by severity and predict exacerbations and hospitalizations.
Materials and methods
Design and study population
We conducted a prospective and observational study of adult patients with the previous diag-
nosis of bronchiectasis attending the specialized outpatient clinic of a tertiary care university
hospital in Barcelona during the period 2011–2015.
We excluded patients with, a) severe immunosuppression, such as in solid-organ or bone-
marrow transplantation or HIV/AIDS, or receiving chemotherapy or other immunosuppres-
sive drugs (20 mg prednisone-equivalent per day for 2 weeks or more); b) active tuberculosis;
c) cystic fibrosis (CF); d) pulmonary interstitial disease; and e) COPD or asthma as a primary
respiratory diagnosis.
The diagnosis of bronchiectasis was confirmed by computerized tomography (CT) scan of
lungs performed previous to study recruitment. Aetiology of bronchiectasis had been investi-
gated in all patients according to Spanish guidelines[12]. Chronic bronchial infection was
defined as the presence of at least 2 respiratory isolates (sputum) of the same pathogen in the
previous year (3 months apart)[13].
We used the definition of bronchiectasis exacerbation of the Spanish guidelines[12]. This
guideline defines an exacerbation as an acute presentation of changes in sputum (volume, con-
sistence, purulence or haemoptysis), and/or increased dyspnoea not due to other cause. It may
be accompanied by increased cough, fever, fatigue, malaise, anorexia, weight loss, pleuritic
chest pain, changes in respiratory exploration (onset of abnormal breathing sounds or changes
in previous ones), abnormal radiograph indicative chest infection, impaired respiratory
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function or increase systemic markers of inflammation. Also, it can be associated with changes
in microbial density of colonizing bacteria or the acquisition of a new microorganism.
Data collection and follow-up
Data collection included demographics, vaccinations (influenza and pneumococcal), comor-
bidities (Charlson Comorbidity Index), exacerbations in the previous year, chronic bronchial
infection, pulmonary function test, radiological characteristics of bronchiectasis (CT scan) and
aetiology, long-term antimicrobial therapy (oral antibiotic as macrolides and/or inhaled anti-
biotic) and concomitant medication. BSI and FACED were calculated for all patients. Follow-
up was based on periodic visits every 3–6 months during 1 year.
Outcomes
We classified patients according to the annual frequency of exacerbations at follow-up in two
groups (Low-EXAC: <2/year and High-EXAC:2/year). The authors chose this cut-off based
in a previous analysis of our database that showed a median of 2 exacerbations at previous
year. This factor is one of the major markers of disease activity and is strictly related to progno-
sis in the short- and long-term[7]. Therefore, our primary outcome was patients who have2
exacerbations per year at follow-up (High-EXAC). We also evaluated hospitalizations due to
BE exacerbations.
The study was approved by the local Ethics committee (CEIC 2013/8071) and a written
informed consent was required as prerequisite for subject recruitment.
Statistical analysis
Results were expressed as mean ± standard deviation (SD) for continuous variables and as
frequency (percentage) for categorical variables. Parametric statistics were used for data con-
firmed to have a normal distribution using Kolmogorov-Smirnov test. Differences in continu-
ous variables were analysed using an independent two-tailed t-test or Mann-Whitney U test, as
appropriate. Categorical variables were studied using the chi-square test or Fisher exact test
when necessary.
Classification of severity (BSI and FACED) was stratified into mild, moderate and severe,
according to the original authors’ designations[9, 10]. The Charlson Comorbidity Index (CCI)
also was calculated[14]. We used Cohen’s kappa coefficient (k)[15] to measure the agreement
between the scores’ severity classification. The discrimination of each score was determined by
constructing a Receiver Operating Characteristic (ROC) curve and the area under the curve
(AUC) and 95% confidence intervals (95% CI) were determined[16]. We compared AUC
between scores using the Delong´s test. The cut-off points were calculated arbitrarily by the
authors following the severity classification of the scores (mild vs. moderate/severe). Sensitiv-
ity, specificity, positive predictive value (PPV), negative predictive value (NPV), likelihood
ratios (LR) and odds ratio (OR) were also calculated.
For the modification of FACED, first we identified variables among those not included in
the original FACED score that were associated with exacerbations at 1 year of follow-up using
univariate analysis. Second, variables with clinical rationale and statistically significant
(p<0.05) were entered in a multivariate logistic regression analysis in addition to the 5 items
of the original FACED score. Third, we selected the variable that remained independently
associated with exacerbations after adjusting for the original FACED score variables. The Hos-
mer-Lemeshow goodness-of-fit test was performed to assess the calibration of the models. We
report OR and 95% CI of the logistic regression models. A bootstrapping technique was used
to assess the internal validation and the robustness of the multivariate logistic regression
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models using 1,000 samples[17]. All tests were two-tailed and significance was set at p<0.05.
Data is provided in a supporting information file (S1 File).
Results
General characteristics of the study population
We collected data from 198 consecutive patients with diagnosis of bronchiectasis and excluded
16 patients who do not have all variables available, remaining 182 patients (92%) for analysis.
The general characteristics of the population studied are show in Table 1. The most frequent
aetiologies were post-infectious (47.8%). Overall, 104 (67.5%) patients had an obstructive pat-
tern (FEV1/FVC<70%) and 24 (13.2%) patients had a severe airflow limitation (FEV1<50%).
Chronic bronchial infection was observed in 50 patients (27.5%); Pseudomonas aeruginosa
(PA) being the most frequent 38 (20.9%) followed by Haemophilus influenzae 13 (7.1%), Mor-
axella catarrhalis 3 (1.6%) and Staphylococcus aureus 3 (1.6%).
Overall, in the previous year 47 patients (25.8%) had no exacerbations, 45 (24.7%) suffered
one exacerbation and 90 (49.5%) had 2 or more exacerbations.
During the prospective follow-up of 1 year, 32 patients (17.6%) had only 1 exacerbation, 43
(23.6) had 2 or more exacerbations, and 107 (58.8%) had no exacerbations. Of patients with at
least one exacerbation during follow-up, 65% (49 of 75) required hospitalization. Therefore,
we separated our patients in two groups as was described in methods: Low-EXAC 139 patients
(76.4%) and High-EXAC 43 (23.6%).
FACED classified our patients mainly as of mild or moderate severity, with few patients as
severe; while BSI scored most patients as severe (Table 2). Table 2A shows the classification by
both scores and agreement rates. There was a slight concordance between two scores, BSI ver-
sus FACED (k = 0.17).
Comparison of low-EXAC and high-EXAC patients
High-EXAC patients were older, had high prevalence of PA chronic bronchial infection, worse
CCI score, FEV1, FEV1/FVC, and mMRC scores, and increased use of oral steroids and
chronic inhaled antibiotic, compared with Low-EXAC patients. BE associated to COPD was
more frequent in High-EXAC patients. No differences were observed in radiological pattern of
bronchiectasis at CT and chronic use of inhaled corticosteroids and bronchodilators (Table 1).
Comparison of BSI and FACED in Low-EXAC and High-EXAC patients
We compared the frequency of individual components of FACED and BSI scores between
Low-EXAC and High-EXAC patients (Table 3). For FACED, we found statistically significant
differences for the chronic bronchial infection by PA and age components between Low-
EXAC and High-EXAC. For BSI, we found significant differences between groups in chronic
bronchial infection by PA and age components (as in FACED) and of 2 other components that
are not included in the FACED score: prior hospital admission and prior exacerbations.
Predictive performance evaluations
The discrimination of each score to predict exacerbations (2/year) or hospitalizations (1/
year) are shown in Figs 1 and 2. The AUC was 0.808 (95%CI 0.734–0.882) for BSI and 0.734
(95%CI 0.648–0.821) for FACED regarding exacerbations (p = 0.023 for BSI vs FACED). We
observed a higher sensitivity of BSI in contrast with a higher specificity of FACED using
FACED3 and BSI5 as cut-off points (moderate and severe classes).
Comparison of prognostic bronchiectasis scores and improvement of FACED
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Table 1. General characteristics of the study population (n = 182).
Variable Low-EXAC (n = 139) High-EXAC (n = 43) p-value* All (N = 182)
Demographic
Age (years), mean ± SD 65.3 ± 14.9 76.8 ± 8.7 <0.001 68.0 ± 14.6
Sex (male), n (%) 55 (39.6) 15 (41.9) 0.789 73 (40.1)
BMI (kg/m2), mean ± SD 25.6 ± 4.6 25.4 ± 4.8 0.779 25.6 ± 4.6
Smoking (Current smoker or Ex-smoker), n (%) 62 (44.6) 21 (48.8) 0.626 83 (45.6)
Alcohol (Current or ex-consumer), n (%) 10 (7.7) 2 (4.7) 0.732 12 (6.9)
Influenza vaccine, n (%) 95 (68.4) 32 (74.4) 0.449 127 (69.8)
Pneumococcal vaccine, n (%) 78 (56.1) 25 (58.1) 0.815 103 (56.6)
Comorbidities
Arterial hypertension, n (%) 63 (45.3) 24 (55.8) 0.229 87 (47.8)
Diabetes mellitus, n (%) 17 (12.2) 11 (25.6) 0.034 28 (15.4)
Cardiovascular disease, n (%) 30 (21.6) 26 (60.5) <0.001 56 (30.8)
Neurological disease, n (%) 9 (6.5) 5 (11.6) 0.268 14 (7.7)
Chronic renal disease, n (%) 13 (9.4) 7 (16.3) 0.204 20 (10.9)
Chronic liver disease, n (%) 14 (10.1) 6 (13.9) 0.477 20 (10.9)
Neoplastic disease, n (%) 23 (16.6) 13 (30.2) 0.049 36 (19.8)
Charlson Comorbidity Index, mean ± SD 2.2 ± 1.8 3.3 ± 2.1 0.001 2.4 ± 1.9
Bronchial chronic infection
by any microorganism (all), n (%) 31 (22.3) 19 (44.2) 0.005 50 (27.5)
P. Aeruginosa (PA), n (%) 20 (14.4) 18 (41.9) <0.001 38 (20.9)
Other microorganism no-PA, n (%) 14 (10.1) 1 (2.3) 0.200 15 (8.2)
Previous year exacerbations
Exacerbations, mean ± SD 1.5 ± 1.5 2.9 ± 2.1 <0.001 1.8 ± 1.8
Emergency visits, mean ± SD 0.4 ± 0.8 2.1 ± 2.1 <0.001 0.8 ± 1.4
Hospitalization, mean ± SD 0.2 ± 0.5 1.8 ± 1.9 <0.001 0.6 ± 1.2
Spirometry
FEV1% of pred., mean ± SD 73.3 ± 21.2 54.5 ± 17.6 <0.001 70.3 ± 21.8
FEV1/FVC, mean ± SD 64.9 ± 11.5 53.8 ± 11.6 <0.001 63.2 ± 12.2
Bronchiectasis’ aetiology
Idiopathic, n (%) 28 (20.1) 7 (16.3) 0.574 35 (19.2)
Post-infectious, n (%) 68 (48.9) 19 (44.2) 0.587 87 (47.8)
Associated to COPD, n (%) 11 (7.9) 10 (23.3) 0.006 21 (11.5)
Associated to Asthma, n (%) 18 (12.9) 4 (9.3) 0.604 22 (12.1)
Others, n (%) 14 (10.1) 3 (6.9) 0.766 17 (9.3)
Dyspnoea
mMRC, mean ± SD 1.1 ± 1.1 1.8 ± 0.8 <0.001 1.3 ± 1.1
mMRC2 30 (22.4) 27 (62.8) <0.001 57 (32.2)
Chest CT
Cystic BE, n (%) 16 (11.5) 5 (11.6) 0.983 21 (11.6)
Lobules affected with BE, mean ± SD 3.2 ± 1.7 3.2 ± 1.5 0.922 3.2 ± 1.6
Treatment
Inhaled steroids, n (%) 100 (71.9) 37 (86.1) 0.061 137 (75.3)
Inhaled LAMA, n (%) 60 (43.2) 25 (58.1) 0.085 85 (46.7)
Inhaled LABA, n (%) 102 (73.4) 37 (86.1) 0.088 139 (76.4)
Oral steroids, n (%) 18 (12.9) 11 (25.6) 0.048 29 (15.9)
Theophylline, n (%) 2 (1.4) 2 (4.7) 0.237 4 (2.2)
Chronic inhaled antibiotic, n (%) 7 (5.0) 9 (20.9) 0.001 16 (8.8)
(Continued)
Comparison of prognostic bronchiectasis scores and improvement of FACED
PLOS ONE | https://doi.org/10.1371/journal.pone.0175171 April 6, 2017 5 / 14
Regarding hospitalizations, the AUC was 0.893 (95%CI 0.848–0.938) for BSI and 0.809
(95%CI 0.744–0.875) for FACED (p<0.001 for BSI vs FACED). Again, BSI showed higher sen-
sitivity but lower specificity than FACED.
Modified version of FACED (Exa-FACED)
Table 1 shows that comorbidities (diabetes, cardiovascular and neoplastic diseases), exacerba-
tions history, BE associated to COPD and usual treatment (oral steroids and chronic inhaled
Table 1. (Continued)
Variable Low-EXAC (n = 139) High-EXAC (n = 43) p-value* All (N = 182)
Chronic oral macrolides, n (%) 24 (17.3) 12 (27.9) 0.126 36 (19.8)
Severity Score
FACED, mean ± SD 1.8 ± 1.5 3.2 ± 1.7 <0.001 2.1 ± 1.7
FACED (mild / moderate / severe), % 68 / 28 / 4 33 / 51 / 16 <0.001 59 / 34 / 7
FACED (moderate + severe), n (%) 45 (32.4) 29 (67.4) <0.001 74 (40.7)
BSI, mean ± SD 7.9 ± 4.6 13.2 ± 4.0 <0.001 9.2 ± 4.9
BSI (mild / moderate / severe), % 25 / 32 / 43 5 / 5 / 90 <0.001 20 / 26 / 54
BSI (moderate + severe), n (%) 105 (75.5) 41 (95.4) 0.004 146 (80.2)
Percentages calculated on non-missing data.
* Chi-square test, Fisher’s exact test, Student´s t-test or Mann-Whitney U test, as appropriate.
Abbreviations: SD = Standard deviation. COPD = Chronic obstructive pulmonary disease. FEV1 = Forced expiratory volume in the first second.
FVC = Forced vital capacity. PA = Pseudomonas aeruginosa. CT = Computed tomography. BMI = Body mass index (kg/m2). MRC = Medical Research
Council dyspnoea scale (score 1 to 5). mMRC = modified MRC scale (score 0 to 4). BE = bronchiectasis. LAMA = long-acting muscarinic antagonist.
LABA = long-acting beta-agonist.
https://doi.org/10.1371/journal.pone.0175171.t001
Table 2. Classification of patients by BSI versus FACED (2A) or Exa-FACED (2B) scores, and FACED versus Exa-FACED (2C) scores. (Total
N = 182)
2A.
BSI FACED Agreement
Mild Moderate Severe
Mild 36 0 0 Kappa = 0.166 (p<0.001). Concordance 36.8%
Moderate 29 18 0
Severe 43 43 13
2B.
BSI Exa-FACED Agreement coefficient
Mild Moderate Severe
Mild 34 2 0 Kappa = 0.269 (p<0.001). Concordance 47.3%
Moderate 26 21 0
Severe 28 40 31
2C.
FACED Exa-FACED Agreement coefficient
Mild Moderate Severe
Mild 88 20 0 Kappa = 0.643 (p<0.001). Concordance 79.1%
Moderate 0 43 18
Severe 0 0 13
Data are expressed as n.
https://doi.org/10.1371/journal.pone.0175171.t002
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antibiotic) are more frequent in the HIGH-EXAC patients, apart from other variables already
included in the BSI or FACED score. The variables chosen for being statistically significant
variables, with clinical relevance and not included in the original FACED score, are reported
in Table 4. After multivariate adjustment, the only variable which remained independently
associated with exacerbations was the history of 2 or more exacerbations in the last year
(Table 4). Additionally, as previous hospitalizations are associated with exacerbations, we
Table 3. Comparison of BSI and FACED according to their components (n = 182).
Score Component (points) Low-EXAC (N = 139) High-EXAC (N = 43) p-value*
FACED
FEV1% 50% (0 point) 124 (89.2) 34 (79.1) 0.086
<50% (2 points) 15 (10.8) 9 (20.9)
Age 70 years (0 point) 79 (56.8) 10 (23.3) <0.001
>70 years (2 points) 60 (43.2) 33 (76.7)
Chronic PA No (0 point) 119 (85.6) 25 (58.1) <0.001
Yes (1 point) 20 (14.4) 18 (41.9)
CT extension 1–2 lobes (0 points) 61 (43.9) 16 (37.2) 0.439
>2 lobes (1 points) 78 (56.1) 27 (62.8)
Dyspnoea mMRC 0–2 (0 points) 133 (95.7) 35 (81.4) 0.002
mMRC 3–4 (1 points) 6 (4.3) 8 (18.6)
BSI
Age <50 (0 point) 25 (17.9) 0 (0) <0.001
50–69 (2 point) 50 (35.9) 10 (23.2)
70–79 (4 point) 36 (25.9) 14 (32.6)
80 (6 point) 28 (20.2) 19 (44.2)
BMI <18.5 (2 point) 134 (96.4) 41 (95.4) 0.669
18.5 (0 point) 5 (3.6) 2 (4.6)
FEV1% >80% (0 point) 57 (41.0) 21 (48.9) 0.058
50–80% (1 point) 67 (48.2) 13 (30.2)
30–49% (2 points) 13 (9.4) 6 (13.9)
<30% (3 points) 2 (1.4) 3 (7.0)
Prior hospital admission No (0 points) 67 (48.2) 4 (9.3) <0.001
Yes (5 points) 72 (51.8) 39 (90.7)
Prior exacerbations 0–2 (0 points) 110 (79.1) 20 (46.5) <0.001
3 (2 points) 29 (20.9) 23 (53.5)
MRC 1–3 (0 points) 133 (95.7) 35 (81.4) 0.002
4 (2 points) 4 (2.9) 8 (18.6)
5 (3 points) 2 (1.4) 0 (0)
PA colonization No (0 points) 119 (85.6) 25 (58.1) <0.001
Yes (3 points) 20 (14.4) 18 (41.9)
No PA colonization No (0 points) 125 (89.9) 42 (97.7) 0.200
Yes (1 points) 14 (10.1) 1 (2.3)
Radiological severity No (0 point) 60 (43.2) 15 (34.9) 0.335
>3 lobes or cystic BE (1 point) 79 (56.8) 28 (65.1)
Data are expressed as n (%).
* Chi-square test or Fisher’s exact test, as appropriate.
Abbreviations: FEV1 = Forced expiratory volume in the first second. PA = Pseudomonas aeruginosa. CT = Computed tomography. BMI = Body mass index
(kg/m2). MRC = Medical Research Council dyspnoea scale (score 1 to 5). mMRC = modified MRC scale (score 0 to 4). BE = bronchiectasis.
https://doi.org/10.1371/journal.pone.0175171.t003
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performed another multivariate analysis model (data not show) changing the independent var-
iable of exacerbations for the variable “history of 1 or more hospitalization due an exacerbation
last year”, and, as we seen previously, only this variable (hospitalization) was predictive for
exacerbations at follow-up independently of the 5 items of the FACED (OR 4.69; 95%CI 1.88–
11.69; p = 001). The internal validation using bootstrapping demonstrated robust results with
small 95% CI around the original coefficients.
Therefore, we decided to modified the FACED incorporating a new item for “exacerba-
tions” (considering positive the presence of2 exacerbations or1 hospitalization due an
exacerbation last year) to the original FACED score (the Exa-FACED). After rounding the β-
coefficient for the new variable, the presence of this item assigned 1 point to the total score
(Table 5), which punctuates from 0 to 8 (instead of 0–7 of the original score).
Fig 1. ROC curve for2 exacerbations at 1-year of follow-up. Abbreviations: Sens = sensitivity; Spec = specificity;
PPV = positive predictive value; NPV = negative predictive value; GV: global value; LR+ = positive likelihood ratio; LR- = negative
likehood ratio; OR = odds ratio; NA = non-available.
https://doi.org/10.1371/journal.pone.0175171.g001
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Because of the short period of follow-up (1 year), we did not evaluate the prediction of mor-
tality as for the original FACED score, but decided to use the same severity stratification of
FACED: mild 0–2 points, moderate 3–4 points or severe 5 points.
We reclassified our cohort with the new score and we observed a new distribution which is
intermediate between FACED and BSI particularly for mild and severe classes (the percentage
of moderate patients remains stable in all scores). In fact, Exa-FACED classifies patients as
mild in 48.4% (FACED 59.3%; BSI 19.8%), moderate in 34.6% (FACED 33.5%; BSI 25.8%) and
severe in 17.0% (FACED 7.2%; BSI 54.4%). The concordance between Exa-FACED and BSI
was fair (k = 0.27) but higher than that observed between FACED and BSI (Table 2).
A ROC curve was also constructed for Exa-FACED and sensitivity and specificity was cal-
culated considering positive moderate and severe classes (Exa-FACED3) as cut-off point.
For the risk of2 exacerbations/year (Fig 1), the AUC was 0.760 showing a similar sensitivity
Fig 2. ROC curve for1 hospitalizations at 1-year of follow-up. Abbreviations: Sens = sensitivity; Spec = specificity;
PPV = positive predictive value; NPV = negative predictive value; GV: global value; LR+ = positive likelihood ratio; LR- = negative
likelihood ratio; OR = odds ratio; NA = non-available.
https://doi.org/10.1371/journal.pone.0175171.g002
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than BSI, with and intermediate specificity between BSI and FACED. There was a significant
difference in AUC of Exa-FACED with FACED (p = 0.039) but no with BSI (p = 0.114). For
the risk of1 hospitalizations/year (Fig 2) the AUC was 0.820 and it proved to have a high
sensitivity with an intermediate specificity. There was a significant difference in AUC with BSI
(p = 0.001) but no with FACED (p = 0.347).
Discussion
The main findings of this study were the following:
1. There were some differences between patients with low or high frequency of exacerbations
at follow-up.
Table 4. Univariate and multivariate analysis of variables associated with the risk of 2 or more exacerbations.
Univariate analysis Multivariate analysis (*)
Variables OR 95% CI p-value OR 95% CI p-value β-Coefficient
CCI 3 2.39 1.19–4.80 0.014 1.46 0.64–3.31 0.365 0.378
Exacerbation  2/last year 4.06 1.89–8.72 <0.001 2.57 1.07–6.15 0.034 0.944
BE associated to COPD 3.53 1.38–9.01 0.008 2.44 0.79–7.54 0.120 0.894
Oral steroids 2.31 0.99–5.38 0.052 - - - -
Chronic inhaled antibiotic 4.99 1.73–14.37 0.003 2.29 0.62–8.45 0.214 0.829
* The 5 items of the original FACED score (Pseudomonas aeruginosa chronic infection, dyspnoea by mMRC score, forced expiratory volume in the first
second, age in years, and number of lobes affected with bronchiectasis at the CT) were additionally included in the logistic regression model. Hosmer and
Lemeshow goodness-of-fit test: p = 0.666.
https://doi.org/10.1371/journal.pone.0175171.t004
Table 5. Exa-FACED score.
Severity marker Points
Pseudomonas aeruginosa chronic infection
No 0
Yes 1
Dyspnoea mMRC score
0-II 0
III-IV 1
FEV1
 50% of predicted 0
< 50% of predicted 2
Age
< 70 years 0
 70 years 2
Number of lobes involved
1–2 0
> 2 1
 2 exacerbations and/or 1 hospitalizations due to an exacerbation
(*)
No 0
Yes 1
An overall score from 0 to 8 points is derived as a sum of the scores for each variable. Severity classification:
mild (0–2), moderate (3–4), severe (5).
* Additional item
https://doi.org/10.1371/journal.pone.0175171.t005
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2. Both scores (BSI and FACED) classified our patients very differently and there was a poor
concordance between the two scores.
3. BSI had a better predictive capacity than FACED for the occurrence of exacerbations or
hospitalization due to an exacerbation at follow-up.
4. The inclusion of a new item to the original FACED, “Exacerbations”, improved the predic-
tive capacity of this score to be almost similar to BSI but with less complexity to fill it. We
called this modified version “Exa-FACED”.
A correct stratification by severity is fundamental in order to improve the clinical manage-
ment of patients, allowing appropriate preventive and therapeutic interventions and also to
facilitate research in the field in order to properly analyse and interpret research data and to
identify patients for clinical trials.
BSI and FACED were validated by large observational single-centre and multicentre studies
[9–11, 18]. In our cohort of BE patients, with a higher proportion of PA chronic respiratory
infection (21%, consistent with the data described in the literature[19, 20]), we observed sub-
stantial differences in the severity stratification by both scores and a poor concordance
between (Table 2). As expected, the severity stratification by FACED and BSI showed relevant
differences in the patient distribution by severity. FACED scored most patients as mild and
BSI scored most as severe.
Minov et al.[21] achieved a similar distribution of disease severity by BSI and FACED, but the
study showed some underlying limitations, principally a small sample size (n = 37) and a low pro-
portion of patients with PA chronic bronchial infection (8%). On the contrary, in a single-centre
cohort of 91 patients with the same rate of chronic PA (22%)[18] and in a multicentre study[11]
of 1612 patients, similar classification differences were found in the severity assessment, as we
observed. Also, a proportion of patients had a discordant classification; Ellis et al.[18] scored
severe in BSI but mild in FACED in 11 subjects out of 74 (maximal discordance in 15% of the
population), and we scored the same in 43 subjects out of 182 (maximal discordance in 24%).
Causes of different severity stratification by FACED and BSI
In order to investigate the differences between the two scores we compared the prevalence of
individual items composing the scores in our 2 groups of BE patients. We found significant
difference in 5 variables out of 9 in the BSI score: age, dyspnoea, chronic infection by PA and
the presence of prior exacerbations and hospitalizations (see Table 3). We therefore believe
that the main causes of the observed differences are the different punctuation of PA chronic
bronchial infection, which has been related to an increase in the risk of exacerbations and mor-
tality in BE, and the presence of exacerbations and hospitalizations[7, 22–25] which are not
considered in FACED.
If we analyse the burden of these significantly different variables (PA, exacerbations, hospi-
talizations) for each score, we observe that they contribute more or exclusively to BSI than to
FACED, resulting in a higher punctuation and a tendency to classify patients as moderate or
severe with BSI. Merely by having a hospital admission due to exacerbation in the previous 2
years, BSI automatically classifies the patient as moderate (5 points out of 5) and contributes to
more than 50% (5 points out of 9) to the severe class, while this parameter is not taken into
consideration with FACED. Similarly, suffering3 exacerbations provides 40% of the punctu-
ation for moderate (2 points out of 5) and more than 20% for the severe class (2 points out of
9). This variable is neither considered in FACED.
Secondly, the contribution of chronic bronchial infection by PA to the severity punctuation
is superior in BSI than in FACED, both in the moderate (BSI 60% [3 points out of 5]; FACED
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33% [1 point out of 3]) and the severe (BSI 33% [3 points out of 9]; FACED 20% [1 point out
of 5]) class. Finally, we also found a greater contribution of other variables to the BSI than to
the FACED punctuation, although some of them were not significantly different between the 2
groups: age (for all the divisions 50–69, 70–79 and80 years), low BMI and chronic bronchial
infection by other microorganisms (non-PA).
Ability to predict exacerbations and hospitalizations
Our results show that neither BSI nor FACED score are excellent systems to predict exacerba-
tions or hospitalizations in BE patients. However, in our cohort BSI had a superior ability to
predict exacerbations compared with FACED, and especially with those exacerbations that
require hospitalization. Nevertheless, BSI also shows a lower specificity than FACED, probably
due to the fact that it considers numerous different items in the scoring system.
Exa-FACED, a modified version of FACED
Since none of the scores showed an excellent ability to predict exacerbations and hospitaliza-
tions, and considering the differences observed between both scores, we decided to modify the
FACED score. This score is potentially easy to use in clinical practice compared to BSI (5
dichotomized variables in FACED vs. 9 variables with different point values in BSI) but it is
not validated to predict exacerbations[10]. With this modified version, we intend to increase
the predictive capacity of FACED for exacerbations and hospitalizations and to maintain its
specificity (superior in FACED than in BSI) and ease of use.
Actually, with the new Exa-FACED we achieved an intermediate classification of our
patients by severity, scoring for mild, moderate and severe in percentages between BSI and
FACED. This more balanced distribution might have a better association with disease activity
and severity. Besides, the correlation between Exa-FACED and BSI is better than the correla-
tion between the original FACED and BSI but it still remains weak. Also, Exa-FACED proved
to predict the risk of exacerbations almost like BSI and more than FACED. However, Exa-
FACED demonstrated to predict hospitalizations less then BSI but similarly to FACED score.
Since FACED score was already validated for mortality risk, we are sufficiently confident
with the fact that Exa-FACED should maintain the same prognostic value in terms of mortal-
ity, becoming overall an ideal prognostic score of both exacerbations and mortality in clinical
practice due to its accompanying ease of use.
Potential limitations and strengths of the study
The current study has some limitations. First, it is a single-centre study with a relatively small
number of patients, which could have certain influence on the obtained data and their inter-
pretation. Secondly, it does not include a long-term follow-up after 1 year, lacking the ability
to prove mortality prediction of the different scores. Although we did an internal validation
with bootstrapping technique, the Exa-FACED will require an external validation by further
international studies including larger populations.
Among the strengths of the present study, it is important to notice the broad characteriza-
tion of our patients, including a deep analysis of the aetiology and exacerbations, because of a
follow-up in a specialized centre by professionals with experience in bronchiectasis. Moreover,
our study is proposing a new and better tool for assessment of severity and prognosis in BE
(Exa-FACED) that may easily be applied to clinical practice and dedicated to research in the
field.
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Conclusions
As we expected, BSI and FACED classify our patients very differently. BSI showed a superior
ability to predict exacerbations and hospitalizations compared with FACED. Furthermore, we
demonstrated that a modified version of FACED score incorporating the variable “exacerba-
tions” and/or “hospitalizations” better classifies severity and risk of future exacerbations and
hospitalizations in our cohort of patients. We support the use of Exa-FACED for clinical prac-
tice due to its ability to predict exacerbations, hospitalizations and mortality (the latter as
widely demonstrated for FACED[10]) and its ease of use.
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